

Etienne Cavalier (1), Véronique Huberty (2), Catherine Cormier (3), Jean-Claude Souberbielle (4)

(1) Department of Clinical Chemistry, University Hospital of Liege, University of Liege, Belgium

(2) Laboratoire de Biologie Clinique, Centre Hospitalier Peltzer-La Tourelle, Verviers, Belgium

(3) Service de Rhumatologie, Hôpital Cochin, APHP, Paris, France

(4) Service d'Explorations Fonctionnelles, Hôpital Necker-Enfants Malades and Faculté de Médecine, Centre de Recherche Croissance et Signalisation (INSERM U845), Université Paris Descartes, Paris, France

Corresponding author :

Dr Etienne Cavalier  
Department of Clinical Chemistry  
University Hospital of Liege  
Domaine du Sart-Tilman  
B-4000 Liege, Belgium  
Tel: +32 4 3667692  
Fax: +32 4 3667691

Running title: Overestimation of 25(OH)D with automated IDS elisa.

[Etienne.cavalier@chu.ulg.ac.be](mailto:Etienne.cavalier@chu.ulg.ac.be), [Veronique.huberty@chplt.be](mailto:Veronique.huberty@chplt.be), [catherine.cormier@cch.aphp.fr](mailto:catherine.cormier@cch.aphp.fr),  
[jean-claude.souberbielle@nck.aphp.fr](mailto:jean-claude.souberbielle@nck.aphp.fr),

l EC) have frequently been contacted by different  
physicians or clinical biologists who wanted to have an expert point of view on patients  
presenting very high 25-hydroxy vitamin D (25OHD) results (between 150 and >300 ng/mL).  
All of these patients had indeed received the equivalent of 400,000 IU of vitamin D3 over a 2-  
month period (according to a supplementation protocol that we proposed in late 2008 (1)) and  
these colleagues were thinking that they had induced vitamin D intoxication. As the patients  
presented strictly normal serum and urine calcium levels, we were able to reassure them.  
However, after investigation, we noticed that in all cases, 25OHD had been measured with the  
IDS EIA kit (Boldon, UK) adapted on various open automated platforms (*i.e.* Evolis,  
Triturus, Etimax, DSX, *et al.*). When we had the opportunity to control these high-levelled  
samples with the DiaSorin RIA kit (Stillwater, MN), we observed concentrations ranging  
between 50 and 80 ng/mL. We thus suspected that the correct values were given by the  
DiaSorin RIA, as we have shown that this technique matched well even in high 25OHD  
values with a tandem mass spectrometry assay performed in a British reference laboratory  
(2). To investigate these apparent discrepancies, we initiated a comparison study between  
DiaSorin RIA and IDS EIA adapted on two different open automated analyzers, focusing  
on samples in which high 25OHD levels had been found with DiaSorin RIA in our  
laboratories. In the first part of the study, 78 samples presenting 25OHD levels of 30-84  
ng/mL (mean  $\pm$ SD: 55.5 $\pm$ 12.6 ng/mL; 56 of them with a concentration of 50-84 ng/mL) were  
assayed in Liège with the IDS EIA adapted on a DSX platform (Dynex Technologies,  
Chantilly, VA, USA). In the second part, 72 samples presenting 25OHD concentration  
between 50 and 99 ng/mL (mean  $\pm$ SD: 62.4 $\pm$ 13.9 ng/mL) were assayed in Paris with the IDS  
EIA adapted on the Evolis platform (BioRad, Marne la Coquette, France). Both groups of  
samples were also assayed the same days with the IDS EIA performed manually by an  
experienced technician. All the measurements were performed according to the analytical

ers and when a concentration >100 ng/mL was found with the IDS EIA (either « automated » or « manual »), the serum was diluted 1 : 2 and re-assayed.

Combined together, our results showed that the « automated » IDS EIA produced 25OHD concentrations (mean  $\pm$  SD: 87.3 $\pm$ 65.6 ng/mL) that were significantly higher ( $p<0.0001$ ) than those obtained with the DiaSorin RIA (58.9 $\pm$ 12.6 ng/mL) and with the IDS EIA run manually (59.9 $\pm$ 38.6 ng/mL). Even if the manual IDS EIA gave results that were only slightly but significantly ( $p=0.03$ ) higher than those of the DiaSorin RIA, two samples presented however a concentration that was still out of range (>154 ng/mL), even after a 1:2 dilution. The Bland-Altman plot showed an obvious systematic bias that started at a mean level close to 50 ng/mL (Figure 1A). This bias was much less obvious when comparing the DiaSorin RIA and the manual IDS EIA (Figure 1B).

Our results, obtained in two laboratories which used two different automated analyzers, showed that the automated IDS EIA gave frankly higher concentrations than the DiaSorin RIA when values measured with the RIA are higher than 50-60 ng/mL. This may have important clinical consequences as a physician who finds a 25OHD concentration >80-100 ng/mL in one of his vitamin D-treated patient will probably stop the vitamin D supplementation. This situation may become quite frequent as many experts consider that a serum 25OHD level above 30 ng/mL is required for an optimal vitamin D status (1;3-7), and that the dietary recommended intakes (DRI) for vitamin D are insufficient to reach this optimal range. Thus, different protocols for vitamin D supplementation that use dosages that are much higher than the DRI, bringing the 25OHD level of vitamin D insufficient patients to a mean level close to 40-50 ng/mL, have been published recently (1;3;6-9). Interestingly, our finding was not detectable through the vitamin D External Quality Assessment Scheme (DEQAS) as, for all the DEQAS samples tested in 2009 ( $n=20$ ), the IDS « automated » EIA



are very close to those produced by the DiaSorin RIA, and to the GAN Laboratory Trimmed Meanö (ALTM). This may be explained by the fact that the ALTM of the 2009 DEQAS sample with the highest concentration was around 37 ng/mL, which is in agreement with our finding that the systematic overestimation with the IDS EIA seems only present for serums with a DiaSorin RIA 25OHD level of 50 ng/mL or more. It may be thus very useful that the DEQAS proposes, in a near future, at least one serum sample containing a 25OHD concentration of approximately 80-100 ng/mL. Similarly, other studies that compared the automated IDS EIA kit with the DiaSorin RIA (10-12) did not report such a bias but used samples with concentrations mostly in the range of 10-60 ng/mL. One study (10) even reported a modest positive bias (the DiaSorin RIA giving higher levels than the automated IDS EIA) for concentrations mostly between 5-40 ng/mL.

We don't have clear explanation for this bias; Older RIA's, both DiaSorin and IDS, are performed using sample destruction with acetonitrile. That means that samples are deproteinized and delipidated prior to assay. This technique removes all vitamin D binding protein (DBP) and other matrix components that have the capacity to interfere with the assay. The newer 25OHD assays try to remove the 25OHD from its DBP-binding pocket with various displacement techniques such as pH. This type of assay leaves a somewhat functional DBP and all other serum components that may contribute to unwanted matrix effects. In the case of the manual IDS EIA the effects are not so noticeable although it still seems to occur at 25OHD levels > 70 ng/ml. For some reason this matrix problem is much worse in the IDS automated procedure. The exact cause for this will be difficult to determine and whether the problem is similar with other automated analyzers will deserve other studies.

In conclusion, we suggest to the users of the IDS EIA to use this kit in its "manual" procedure rather than to adapt it on an automated platform until clarification and correction of the problem is achieved. We also suggest to interpret very cautiously a 25OHD level >100 ng/mL

try to know what kind of vitamin D supplement the

2 patient has taken), to re-measure the sample after dilution, and to use another assay-method if

3 the high value persists. Finally, we think that proficiency testing providers, like UK-DEQAS,

4 should integrate high-levelled samples in their schemes.

5

6

7 Acknowledgements: We would like to thank Pr Bruce Hollis for the discussion aiming to help

8 in understanding the discrepancies observed. We also thank IDS for the donation of the EIA

9 kits

10

## Reference List

1. Souberbielle JC, Prie D, Courbebaisse M, Friedlander G, Houillier P, Maruani G, Cavalier E, Cormier C 12/2008 [Update on vitamin D and evaluation of vitamin D status]. *Ann Endocrinol (Paris)* 69:501-510.
2. Cavalier E, Wallace AM, Knox S, Mistretta VI, Cormier C, Souberbielle JC 11/2008 Serum Vitamin D Measurement May Not Reflect What You Give to Your Patients .. *J Bone Miner Res* 23:1864.
3. Adams JS, Hewison M 2/2010 Update in vitamin D. *J Clin Endocrinol Metab* 95:471-478.
4. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B 7/2006 Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 84:18-28.
5. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R 7/2005 Estimates of optimal vitamin D status. *Osteoporos Int* 16:713-716.
6. Holick MF 7/19/2007 Vitamin D deficiency. *N Engl J Med* 357:266-281.
7. Hollis BW 2/2005 Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. *J Nutr* 135:317-322.
8. Jean G, Souberbielle JC, Chazot C 7/21/2009 Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. *Nephrol Dial Transplant*.
9. Przybelski R, Agrawal S, Krueger D, Engelke JA, Walbrun F, Binkley N 11/2008 Rapid correction of low vitamin D status in nursing home residents. *Osteoporos Int* 19:1621-1628.
10. Hypponen E, Turner S, Cumberland P, Power C, Gibb I 12/2007 Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. *J Clin Endocrinol Metab* 92:4615-4622.
11. Kimball SM, Vieth R 11/2007 A comparison of automated methods for the quantitation of serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. *Clin Biochem* 40:1305-1310.
12. Roth HJ, Schmidt-Gayk H, Weber H, Niederau C 3/2008 Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. *Ann Clin Biochem* 45:153-159.



**PDF**  
Complete

*Your complimentary  
use period has ended.  
Thank you for using  
PDF Complete.*

[Click Here to upgrade to  
Unlimited Pages and Expanded Features](#)

of the comparison of the 25OHD levels measured with  
the IDS EIA (Figure 1A), or the "manual" IDS EIA  
(Figure 1B) in 78 serum samples assayed in the Clinical Chemistry Laboratory of the Liège  
University Hospital (open circles) and 72 serum samples assayed in the Hormonology  
Laboratory of the Necker Hospital in Paris (crosses). A systematic negative bias is obvious in  
Figure 1A (lower values with the DiaSorin RIA).




Figure 1B

